Karyopharm Therapeutics
KPTI
$1.10
Share price
3.77%
Change (1 day)
-71.43%
Change (1 year)
Categories
P/S ratio for Karyopharm Therapeutics (KPTI)
P/S ratio as of April 2024 (TTM): 0.8773
According to Karyopharm Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.877285. At the end of 2023 the company had a P/S ratio of 0.6784.
P/S ratio history for Karyopharm Therapeutics from 2013 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 0.6784 | -72.32% |
| 2022 | 2.45 | 5.85% |
| 2021 | 2.32 | -78.04% |
| 2020 | 10.5 | -65.6% |
| 2019 | 30.6 | 63.1% |
| 2018 | 18.8 | -93.34% |
| 2017 | 282 | -88.79% |
| 2016 | > 1000 | 32.44% |
| 2015 | > 1000 | -64.59% |
| 2014 | > 1000 | 206.35% |
| 2013 | > 1000 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | 4.64 | 428.98% | 🇺🇸 USA |
 Merck MRK | 5.48 | 524.98% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 1.99 | 126.49% | 🇺🇸 USA |
 Exelixis EXEL | 3.82 | 335.70% | 🇺🇸 USA |